In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Transactions of the Association of American Physicians

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 2534707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody.

  1989cited by this paper
• Early experience with anti-Tac in clinical renal transplantation.

  1989cited by this paper
• Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantation.

  1988cited by this paper
• Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects

  1988cited by this paper
• The bimolecular structure of the interleukin 2 receptor.

  1988cited by this paper
• Prolongation of primate renal allografts with anti-Tac monoclonal antibody.

  1988cited by this paper
• Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2.

  1987cited by this paper
• Selective immunosuppression with anti‐interleukin 2 receptor‐targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts

  1987cited by this paper
• Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with cyclosporin.

  1986cited by this paper
• Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

  1986cited by this paper
• Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.

  1983cited by this paper

• Interleukin 2 receptor antagonists for kidney transplant recipients.

  2010cites this paper
• Signaling T‐Cell Survival and Death by IL‐2 and IL‐15

  2005cites this paper
• Interleukin 2 receptor antagonists for kidney transplant recipients.

  2004cites this paper